Does PD-1 blockade play a decisive role in the pathological complete remission of unresectable MSS, BRAF V600E-mutated metastatic colorectal cancer: A case report.

ABSTRACT:

Background

Colorectal cancer (CRC) ranks third in highest incidence among human cancers. With the continuous development of anti-cancer drugs, CRC patients are treated more and more effectively. However, the treatment of patients with unresectable metastatic CRC (mCRC) remains a core point for surgeons worldwide, especially for those with microsatellite stability (MSS) and BRAF V600E mutation, who have been reported to have the worst prognosis.

Case description

We report a case of pathological complete remission in a patient with unresectable MSS, BRAF V600E-mutated metastatic rectal cancer after using Vemurafenib and Cetuximab in combination with Camrelizumab.

Conclusions

This case suggested that Vemurafenib and Cetuximab combined with Camrelizumab is effective in th

SUBMITTER: Tan L 

PROVIDER: S-EPMC9880525 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature